BBNX Form 4: CFO Exercises 4,982-Share Option and Executes 10b5-1 Sales

Rhea-AI Filing Summary

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions dated 10/03/2025. He acquired 4,982 shares on that date through exercise of an employee stock option with an exercise price of $5.10, bringing his beneficial ownership to 49,023 shares immediately after the acquisition. On the same date he sold 3,828 shares at a weighted average price of $21.5172 and 1,154 shares at a weighted average price of $22.2778, executed pursuant to a Rule 10b5-1 plan adopted on 05/15/2025. After these transactions his reported beneficial ownership is 44,041 shares. The option shares vest in 48 equal monthly installments measured from 09/14/2023.

Positive

• Transaction executed under a Rule 10b5-1 plan (adopted 05/15/2025), providing predetermined, non‑discretionary sale mechanics
• Option exercise increased holdings by 4,982 shares at an exercise price of $5.10, showing use of vested compensation to acquire shares

Negative

• Total beneficial ownership declined from 49,023 shares to 44,041 shares after the sales on 10/03/2025
• CFO sold 4,982 shares in total (3,828 + 1,154), which may reduce insider share concentration

Insights

Insider Transactions Analyst

Concurrent option exercise and planned sales reduced ownership to 44,041 shares.

The CFO exercised an employee stock option to acquire $4,982 shares at an exercise price of $5.10 on 10/03/2025 while selling 3,828 and 1,154 shares at weighted averages of $21.5172 and $22.2778 under a Rule 10b5-1 plan adopted 05/15/2025. The filings show the mechanics: exercise increased holdings before pre‑planned sales reduced them to 44,041.

Dependencies and risks include the fact that sales were executed under a documented plan, which limits interpretive value regarding discretionary insider intent. Monitor quarterly filings and any future Form 4s for material changes in ownership or additional 10b5-1 activity within the next 12 months.

Equity Compensation Specialist

Option vesting schedule and exercise price indicate long‑dated compensation alignment.

The option underlying the acquired shares vests in 48 equal monthly installments measured from 09/14/2023, and the exercise price is $5.10. Post-exercise, the filing reports 69,695 total option shares referenced in Table II prior to the transaction adjustments shown.

Key items to watch: remaining unvested option tranches and future exercises that may dilute equity; review subsequent equity grants disclosed in proxy materials or Form 4s over the next 12 months to assess ongoing compensation dilution.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		M		4,982	A	$5.1	49,023	D
Common Stock	10/03/2025		S(1)		3,828	D	$21.5172(2)	45,195	D
Common Stock	10/03/2025		S(1)		1,154	D	$22.2778(3)	44,041	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	10/03/2025		M			4,982	(4)	09/13/2033	Common Stock	4,982	$0	69,695	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

2. The weighted average sale price for the transaction reported was $21.5172 and the range of prices were between $21.04 and $22.0144. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The weighted average sale price for the transaction reported was $22.2778 and the range of prices were between $22.0438 and $22..47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics CFO Stephen Feider file on Form 4 (BBNX)?

The filing reports an option exercise for 4,982 shares at an exercise price of $5.10 and sales of 3,828 and 1,154 shares on 10/03/2025.

Were the sales executed under a Rule 10b5-1 plan?

Yes. The seller disclosed the transactions were made pursuant to a Rule 10b5-1 plan adopted on 05/15/2025.

What is Stephen Feider’s beneficial ownership after these transactions?

The Form 4 reports final beneficial ownership of 44,041 shares following the reported transactions on 10/03/2025.

What was the weighted average sale price for the reported sales?

The sales had weighted average prices of $21.5172 (range $21.04–$22.0144) and $22.2778 (range $22.0438–$22.47), respectively.

What are the vesting terms for the exercised option?

The shares subject to the option vest in 48 equal monthly installments measured from 09/14/2023.

When was the Form 4 signed?

The Form 4 is signed by Stephen Feider and dated 10/07/2025.